Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease.
Mitchison
D A
DA
Department of Medical Microbiology, St George's Hospital Medical School, London, UK.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D015169:Colony Count, Microbial; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010303:Paromomycin / Q000627:therapeutic use; D012008:Recurrence; D017828:Rifabutin / Q000627:therapeutic use; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D017828:Rifabutin; D010303:Paromomycin; D012293:Rifampin; C018421:rifapentine